基本信息
浏览量:31
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
My research interest is to develop a novel cancer therapeutic modality especially oriented around the molecular regulation of Transforming Growth Factor-beta (TGF-β) signaling that has a dual function in cancer as a tumor suppressor and a tumor promoter depending on the stage of disease progression.
In 2012, I earned a Ph.D. in Department of biomedical science in CHA university, South Korea under the guidance of Dr. Seong-Jin Kim. TGF-β in cancer is involved in growth, epithelial-mesenchymal transition (EMT), metastasis, and tumor immune-suppressive microenvironment. During my Ph.D. program, I found novel regulators such as CBL and Skp2 of TGF-β signaling and revealed the role of the regulators in TGF-β signaling and cancer. Upregulated CBL and Skp2 in cancer inhibited TGF-β-mediated growth suppression. I have also investigated the new role of Smad7 as a mediator of TGF-β signaling. Nuclear Smad7 cooperated with ATM-Mre11-Rad50-Nbs-1 complex in DNA double strand repair TGF-β signaling-independently. I significantly contributed to development of a small molecule Vactosertib, a highly selective type I TGF-β receptor kinase inhibitor, as a novel cancer therapy which advanced to clinical trials for multiple indications by MedPacto Co. Vactosertib showed strong inhibition of TGF-β-mediated EMT and metastasis and enhanced anti-tumor immune activation in the pre-clinical studies. The combination treatment of Vactosertib with chemotherapeutic compounds enhanced a therapeutic effect synergistically in pancreatic cancer model. I also actively involved in the study delineating a novel tumoricidal mechanism of Galangin, an active flavonoid, as an inhibitor of Smad3 linker region phosphorylation that increases TGF-β-mediated apoptosis in cancer models. From postdoctoral fellowship, my research interest extended to investigating novel cancer-specific targets in various clinical biopsies of cancer and developing more efficacious cancer immunotherapy. Through whole genome sequencing and RNA sequencing of gastric cancer patients, I found and delineated the function of cancer-specifically regulated targets such as KIAA1324, fusion genes, and deleted genome hotspots in gastric cancer. I discovered that down regulation of KIAA1324 in gastric cancer showed anti-tumor effects by inhibiting activity of oncogenic GRP78. PPP1R1B-STARD3 fusion gene increased proliferation of gastric cancer cell.
As I transitioned to MD Anderson cancer center, I engaged in the research understanding the relationship between pancreatic cancer mutation burden and chronic pancreatitis which led to identifying the role of novel non-coding RNA in cancer glucose metabolism using various genetic modified mouse model.
In McGovern medical school, I have investigated cancer immunotherapy in pre-clinical model of glioblastoma multiform (GBM) using oncolytic virus and immune checkpoint blockade (ICB). Combination treatment of oncolytic virus expressing immune booster and ICB showed dramatic tumor rejection in GBM mouse model by which I confirmed the increased anti-tumor immune cell population and immunologic memory-mediated tumor rejection in long-term survived mice. Currently in University Hospitals Cleveland Medical Center, I am developing a novel platform of dendritic cell-based cancer vaccine called “PROTEXI” in collaboration with the research team at Celloram Inc. Through extensive pre-clinical studies, it is confidently proved that PROTEXI significantly improves tumor-associated antigen-specific CD8 T cell activation by leveraging CD4T helper function which provide evidence to increase immunotherapeutic efficacy and long-term persistency of immune-mediated tumor suppression in cancer patients. Through my research experiences and collaboration with the groups in academia and bio companies, I developed my expertise to fulfill a novel cancer therapeutic development in the proposed study.
研究兴趣
论文共 40 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Min Hye Noh,Jin Muk Kang, Alexandra A Miller, Grace Nguyen, Minxin Huang,Ji Seon Shim,Alberto J Bueso-Perez,Sara A Murphy,Kimberly A Rivera-Caraballo,Yoshihiro Otani,Eunju Kim,Seung-Hee Yoo,
Neuro-oncology (2024)
Cell Death and Diseaseno. 8 (2023): 1-12
Eunju Kim,Yoon-Jin Kim,Zhiwei Ji,Jin Muk Kang,Marvin Wirianto,Keshav Raj Paudel, Joshua A. Smith,Kaori Ono,Jin-Ah Kim,Kristin Eckel-Mahan, Xiaobo Zhou,Hyun Kyoung Lee,
Cell Death & Diseaseno. 4 (2022): 1-15
Scientific reportsno. 1 (2021): 9219-9219
加载更多
作者统计
#Papers: 39
#Citation: 541
H-Index: 15
G-Index: 23
Sociability: 5
Diversity: 0
Activity: 0
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn